Dashboard
Manage Tickers

ACAD


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

jim-cramer-believes-in-dell-ceo-doesnt-like-bg-foods
Jim Cramer Believes In Dell CEO, Doesn't L...
08/27/2024 12:40:14

Cramer gives his take on E.l.f Beauty, Acadia Pharmaceuticals, B&G Foods, Lucid, SoFi, Dell, Johnson & Johnson, UWM and...

citigroup-maintains-buy-on-acadia-pharmaceuticals-lowers-price-target-to-23
Citigroup Maintains Buy on ACADIA Pharmace...
08/08/2024 19:26:05

Citigroup analyst David Hoang maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $30...

ubs-maintains-buy-on-acadia-pharmaceuticals-lowers-price-target-to-23
UBS Maintains Buy on ACADIA Pharmaceutical...
08/08/2024 13:50:44

UBS analyst Ashwani Verma maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $25 to ...

hc-wainwright--co-reiterates-buy-on-acadia-pharmaceuticals-maintains-27-price-target
HC Wainwright & Co. Reiterates Buy on ACAD...
08/08/2024 11:07:34

HC Wainwright & Co. analyst Andrew Fein reiterates ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and maintains $27 pri...

needham-maintains-buy-on-acadia-pharmaceuticals-lowers-price-target-to-28
Needham Maintains Buy on ACADIA Pharmaceut...
08/07/2024 20:24:28

Needham analyst Ami Fadia maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $30 to ...

cantor-fitzgerald-maintains-overweight-on-acadia-pharmaceuticals-lowers-price-target-to-28
Cantor Fitzgerald Maintains Overweight on ...
08/07/2024 18:36:55

Cantor Fitzgerald analyst Charles Duncan maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Overweight and lowers the pri...

rbc-capital-maintains-outperform-on-acadia-pharmaceuticals-lowers-price-target-to-26
RBC Capital Maintains Outperform on ACADIA...
08/07/2024 15:34:38

RBC Capital analyst Gregory Renza maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Outperform and lowers the price targ...

airbnb-reports-weak-earnings-joins-cryoport-tripadvisor-lyft-and-other-big-stocks-moving-lower-in-wednesdays-pre-market-session
Airbnb Reports Weak Earnings, Joins Cryopo...
08/07/2024 12:56:52

expert-outlook-acadia-pharmaceuticals-through-the-eyes-of-5-analysts
Expert Outlook: ACADIA Pharmaceuticals Thr...
08/07/2024 12:01:23

morgan-stanley-downgrades-acadia-pharmaceuticals-to-equal-weight-lowers-price-target-to-20
Morgan Stanley Downgrades ACADIA Pharmaceu...
08/07/2024 09:29:53

Morgan Stanley analyst Jeffrey Hung downgrades ACADIA Pharmaceuticals (NASDAQ:ACAD) from Overweight to Equal-Weight and lowe...

acadia-pharmaceuticals-sees-fy24-total-revenue-930m-980m-vs-95315m-est
Acadia Pharmaceuticals Sees FY24 Total Rev...
08/06/2024 21:30:45

acadia-pharmaceuticals-q2-2024-gaap-eps-020-beats-018-estimate-sales-241963m-beat-235418m-estimate
ACADIA Pharmaceuticals Q2 2024 GAAP EPS $0...
08/06/2024 20:54:52

ACADIA Pharmaceuticals (NASDAQ:ACAD) reported quarterly earnings of $0.20 per share which beat the analyst consensus estimate o...

acadia-pharmaceuticals-announces-continued-improvements-in-rsbq-and-cgi-i-scores-with-long-term-daybue-treatment-in-phase-3-lavender-and-lilac-studies-daybue-safety-profile-consistent-with-lavender-trial-findings-published-results-show-improved-rett-symptoms-in-patients-completing-lilac-1-and-lilac-2-open-label-extension-studies
Acadia Pharmaceuticals Announces Continued...
07/18/2024 13:09:47

a-closer-look-at-13-analyst-recommendations-for-acadia-pharmaceuticals
A Closer Look at 13 Analyst Recommendation...
07/12/2024 18:01:28

morgan-stanley-maintains-overweight-on-acadia-pharmaceuticals-lowers-price-target-to-28
Morgan Stanley Maintains Overweight on ACA...
07/12/2024 16:52:38

Morgan Stanley analyst Jeffrey Hung maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Overweight and lowers the price ta...

this-vertex-pharmaceuticals-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-thursday
This Vertex Pharmaceuticals Analyst Begins...
06/27/2024 12:41:40

bmo-capital-initiates-coverage-on-acadia-pharmaceuticals-with-outperform-rating-announces-price-target-of-31
BMO Capital Initiates Coverage On ACADIA P...
06/27/2024 09:20:14

BMO Capital analyst Keith Tapper initiates coverage on ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Outperform rating and ann...

expert-ratings-for-acadia-pharmaceuticals
Expert Ratings For ACADIA Pharmaceuticals
06/25/2024 15:00:26

rbc-capital-reiterates-outperform-on-acadia-pharmaceuticals-maintains-29-price-target
RBC Capital Reiterates Outperform on ACADI...
06/25/2024 14:25:29

RBC Capital analyst Gregory Renza reiterates ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Outperform and maintains $29 price ...

acadia-pharmaceuticals-presents-daybue-real-world-evidence-and-additional-data-in-rett-syndrome-at-the-2024-irsf-annual-scientific-meeting
Acadia Pharmaceuticals Presents DAYBUE Rea...
06/18/2024 13:29:47

Acadia Pharmaceuticals, Inc. (NASDAQ:ACAD) today announced that interim data from the open-label real-world LOTUS™ study will b...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION